Latest Ratios: P/E Ratio -5.6x · EV/EBITDA N/A · ROE -109.9%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $869M | $494M | $163M | $122M | $46M | $187M | $394M | $179M | $892M | — | — |
| Enterprise Value | $830M | $455M | $107M | $74M | $-81041961 | $70M | $244M | $110M | $806M | — | — |
| P/E Ratio → | -5.60 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 5.66 | 13.72 | — | — | — | — | — |
| P/B Ratio | 5.42 | 2.74 | 1.19 | 0.97 | 0.22 | 0.90 | 2.98 | 2.24 | 7.12 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | -10.01 | 5.12 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | — | — | — | — | -1315.2% | -530.5% | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | -1062.3% | -530.0% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -109.9% | -109.9% | -94.6% | -56.8% | -41.0% | -42.4% | -83.2% | -114.2% | -226.9% | — | — |
| ROA | -82.8% | -82.8% | -70.5% | -45.2% | -34.9% | -35.8% | -64.3% | -96.5% | -69.3% | -89.2% | -44.7% |
| ROIC | -120.8% | -120.8% | -121.7% | -95.7% | -90.7% | -147.2% | — | -351.5% | — | — | — |
| ROCE | -100.3% | -100.3% | -84.0% | -53.7% | -47.7% | -40.7% | -74.6% | -112.4% | -78.8% | -111.2% | -67.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.18 | 0.21 | 0.13 | 0.01 | 0.04 | 0.09 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.41 | -0.38 | -0.60 | -0.56 | -1.13 | -0.86 | -0.68 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -365.76 | — | — | — | — | — | — | — | — |
Net cash position: cash ($60M) exceeds total debt ($21M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.14 | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 | 5.82 |
| Quick Ratio | 6.14 | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 | 5.82 |
| Cash Ratio | 5.61 | 5.61 | 4.92 | 8.52 | 9.50 | 8.80 | 6.32 | 4.57 | 9.81 | 6.13 | 5.48 |
| Asset Turnover | — | — | — | — | 0.03 | 0.06 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 2.95 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $88M | $41M | $20M | $9M | $7M | $3M | $3M | $2M | $2M | $1M |
Clinical Trial Funding Gap
Based on reported figures, the company trades at a forward EV/EBITDA of 930.77, suggesting that market participants are pricing the stock as a high-risk option on future clinical success rather than reflecting any current fundamental valuation metrics or established commercial earnings power.
The extreme forward multiple indicates that investors are heavily discounting the company's distant, theoretical cash flows, which is typical for pre-revenue biotech entities. This valuation appears highly sensitive to clinical trial readouts, as the lack of a P/E ratio or meaningful P/S multiple leaves the stock without a traditional fundamental floor.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -36.3% in 2026Q1, which highlights the structural inability of the current research-heavy business model to generate positive returns on the capital deployed into its gene therapy pipeline.
The persistent negative ROIC reflects the high cost of specialized manufacturing and clinical development that currently yields no offsetting revenue. This trend suggests that until the company achieves a successful commercial launch, capital allocation will continue to erode shareholder value rather than compound it.
According to recent SEC filings, the company's current ratio has fluctuated significantly, reaching 13.10 in 2026Q1, yet this metric is misleading as it masks the rapid cash burn required to sustain the SGT-003 clinical program against a limited $59.9 million cash position.
While the high current ratio suggests an ability to cover short-term liabilities, the underlying cash burn rate indicates that this liquidity is not a sign of operational strength but rather a temporary buffer. Investors should monitor the company's ability to secure additional funding before this runway is exhausted.
Based on peer comparison data, SLDB trades at a significant discount to commercial-stage competitors like Sarepta Therapeutics, reflecting the substantial clinical and regulatory hurdles the company must clear to prove its next-generation capsid technology is superior to existing market standards.
The valuation gap appears structural, as Sarepta benefits from established revenue streams and regulatory approvals that SLDB lacks. This disparity suggests that the market is correctly identifying the higher risk profile associated with SLDB's unproven clinical assets compared to the more mature peer group.
The current ratio is the most commonly misapplied metric for this business model, as it obscures the reality that the company's assets are primarily cash being consumed by R&D, rather than working capital that supports a self-sustaining, revenue-generating operational cycle.
Analysts should prioritize 'Net Cash Burn' over liquidity ratios like the current or quick ratio, as the latter provide a false sense of security in a pre-revenue firm. A more accurate assessment of the company's health requires evaluating the remaining months of cash runway relative to clinical trial milestones.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLDB stock.
Solid Biosciences Inc.'s current P/E ratio is -5.6x. This places it at the 50th percentile of its historical range.
Solid Biosciences Inc.'s return on equity (ROE) is -109.9%. The historical average is -96.1%.
Based on historical data, Solid Biosciences Inc. is trading at a P/E of -5.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.